Brief: Harbour Biomed Announces Results Of Phase Ib Clinical Trial Of Porustobart In Combination With Toripalimab In Advanced High-Grade Neuroendocrine Neoplasms At Aacr Annual Meeting

HBM Holdings

14/04/2023 19:58

April 14 (Reuters) - HARBOUR BIOMED:
    * HARBOUR BIOMED ANNOUNCES RESULTS OF PHASE IB CLINICAL
TRIAL OF
PORUSTOBART IN COMBINATION WITH TORIPALIMAB IN ADVANCED
HIGH-GRADE NEUROENDOCRINE NEOPLASMS AT AACR ANNUAL MEETING
    * HARBOUR BIOMED - PORUSTOBART IN COMBINATION WITH
TORIPALIMAB
SHOWED PROMISING ANTI-TUMOR ACTIVITY AND AN ACCEPTABLE SAFETY
PROFILE IN PTS
    * HARBOUR BIOMED - ORR AND DCR WERE 38.5% AND 69.2% IN
NEUROENDOCRINE CARCINOMA (NEC) PATIENTS
    * HARBOUR BIOMED- IS ALSO CONDUCTING OTHER CLINICAL STUDIES
OF
COMBINATION THERAPY FOR OTHER ADVANCED SOLID TUMORS

Source text for Eikon:  ID:nPn9jtfHLa 

 ((Reuters.Briefs@thomsonreuters.com;))